Yesterday, we learned of the death of the second French patient to have participated in tests of the artificial heart of Carmat, a high-tech prosthesis that incorporates certain organic parts to limit the formation of blood clots and whose functioning is entirely autonomous.
Carmat quickly indicated that the patient was experiencing circulatory failure and that therefore, consideration had been given to replacing the artificial heart. The 69-year-old patient died from postoperative complications. He will have been kept alive for 9 months thanks to the artificial heart. The previous patient, the first to receive Carmat's heart, died 74 days after the device was placed.
Carmat has thus revealed initial elements of analysis and indicates "The first data from the prosthesis show that its functioning has deteriorated due to a lack of engine control, leading to a decrease in the volume of blood injected into the body."
The group indicates however that despite this malfunction, the fundamental elements of the prosthesis and in particular its biocompatibility and its design are confirmed. Carmat also indicates that "The patient lived almost nine months with the prosthesis leading an almost normal life. The first analyzes at the end of the relatively long period show the biocompatibility of the prosthesis with the body and with the blood. The telemetry data accumulated during the entire duration of the implantation gives the opportunity to pursue more effectively the expertise of the causes of the dysfunction that has appeared. "
The Carmat prosthesis is designed to replace the heart permanently unlike the other prostheses currently available which are only presented as temporary solutions allowing to keep alive the patients awaiting an organ transplant.
It should also be remembered that the tests carried out by Carmat only target terminally ill patients who cannot hope to regain their independence by medication or by a traditional transplant.